Incyte (INCY) – Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Incyte (NASDAQ: INCY) in the last few weeks:

• 4/1/2026 – Incyte was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 3/25/2026 – Incyte had its price target lowered by UBS Group AG from $104.00 to $94.00. They now have a “neutral” rating on the stock.
• 3/25/2026 – Incyte had its “buy” rating reaffirmed by HC Wainwright. They now have a $135.00 price target on the stock.
• 3/24/2026 – Incyte had its “overweight” rating reaffirmed by Barclays PLC.
• 3/17/2026 – Incyte was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 3/16/2026 – Incyte was downgraded by Jefferies Financial Group Inc. from “buy” to “hold”. They now have a $94.00 price target on the stock, down from $120.00.
• 3/9/2026 – Incyte had its “buy” rating reaffirmed by HC Wainwright. They now have a $135.00 price target on the stock.
• 3/2/2026 – Incyte was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 2/18/2026 – Incyte had its price target raised by Barclays PLC from $116.00 to $117.00. They now have an “overweight” rating on the stock.
• 2/14/2026 – Incyte was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 2/11/2026 – Incyte was given a new $102.00 price target by Morgan Stanley.
• 2/11/2026 – Incyte had its price target raised by Stifel Nicolaus from $119.00 to $120.00. They now have a “buy” rating on the stock.
• 2/11/2026 – Incyte had its price target lowered by Royal Bank Of Canada from $95.00 to $92.00. They now have a “sector perform” rating on the stock.
• 2/11/2026 – Incyte had its price target lowered by Wells Fargo & Company from $107.00 to $101.00. They now have an “equal weight” rating on the stock.
• 2/11/2026 – Incyte had its “buy” rating reaffirmed by HC Wainwright. They now have a $135.00 price target on the stock.
• 2/6/2026 – Incyte had its price target raised by Piper Sandler from $102.00 to $110.00. They now have an “overweight” rating on the stock.

Insider Activity at Incyte

In other Incyte news, EVP Mohamed Khairie Issa sold 10,856 shares of Incyte stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $109.07, for a total transaction of $1,184,063.92. Following the completion of the sale, the executive vice president directly owned 66,132 shares in the company, valued at approximately $7,213,017.24. The trade was a 14.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Pablo J. Cagnoni sold 18,667 shares of Incyte stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $94.24, for a total transaction of $1,759,178.08. Following the sale, the insider owned 234,800 shares of the company’s stock, valued at approximately $22,127,552. The trade was a 7.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 17.80% of the company’s stock.

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.